The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

AstraZeneca (NASDAQ:AZN) has announced positive results from a late-stage trial testing Imfinzi (durvalumab) combined with Bacillus Calmette-Guérin (BCG) therapy as a bladder cancer treatment. This ...

BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...

To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...

Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association.

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Bladder cancer is one of the most common cancers worldwide. Men are around four times more likely to develop it than women, ...